Skip to main content

Prostate Cancer Test Deal Forged by Minomic, Cirrus Dx

NEW YORK (360Dx) — Minomic announced today that it has signed an agreement to offer its MiCheck prostate cancer diagnostic in the US through Rockville, Maryland-based CLIA laboratory Cirrus Dx.

According to Sydney-based Minomic — which was originally established in 2002 as a proteomics firm — MiCheck is a blood-based test that measures a number of protein biomarkers, including a proprietary antibody called glypican-1, to diagnose prostate cancer and determine its aggressiveness.

Under the terms of the deal, Cirrus Dx will offer MiCheck in the US as a laboratory-developed test following the completion of internal validation studies, which are expected to conclude by the end of the first quarter. Minomic added that a reimbursement code has been identified for the test and that reimbursement is expected to be available.

Additional terms were not disclosed.

"Being able to offer MiCheck as an LDT through our partnership with Cirrus Dx will provide the company with ... real world data which can be used in subsequent FDA approval submissions, validation of MiCheck and its clinical utility, and, finally, royalty revenues," Minomic Founder and CEO Brad Walsh said in a statement.